Zero to Hero? Scope 3 Emissions – A Strategic Imperative for Pharma Companies Verena Ahnert Read more
Executive Insights Life Sciences & Pharma From Discovery to Launch: Building Next-Generation Investment Governance for Biotech January 13, 2026
Article Travel, Transport & Logistics Building Resilient and Sustainable Healthcare Supply Chains October 15, 2025
Executive Insights Life Sciences & Pharma Behavior-First Biopharma Go-to-Market Strategies October 6, 2025
Smart Chart Life Sciences & Pharma Unlocking Growth: Singapore's Role in Advancing Life Sciences and Medtech Innovations March 10, 2025
Case Study Life Sciences & Pharma Unlocking the Potential of Next-Generation PROTACs: A Strategic Roadmap for R&D Investment March 7, 2025 Our client engaged L.E.K. Consulting to develop a market overview across multiple key therapeutic areas (e.g., oncology, immunology, neuroscience) and…
Case Study Private Equity Future Ready: Comprehensive Operational Due Diligence on a Medtech and Life Sciences… February 24, 2025 A private equity firm approached L.E.K. Consulting to conduct operational due diligence on a promising precision medtech and life sciences engineering…
